Home / PD-L1/B7-H1 / Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Catalog #: 156-B7
24 Citations 21 Reviews Datasheet / COA / SDS
Analyzed by SEC-MALS
Catalog # Availability Size / Price Qty
156-B7-100
156-B7-01M
Best Seller
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein SEC-MALS.
2 Images
Product Details
Citations (24)
FAQs
Supplemental Products
Reviews (21)
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF Summary

Why choose R&D Systems PD-L1 Protein, Fc chimera?

  • Guaranteed Bioactivity and High Purity: Bioactivity tested by functional ELISA and purity determined by SDS-PAGE to be greater than 90%.
  • Lot-to-Lot Consistency: Stringent QC testing performed on each lot to ensure consistent activity and purity.
  • Bulk Quantities Available: Bulk up and save with large mass quantities to meet your research needs. Supply agreements available, partner with us. Please contact us.
  • Most Respected, Most Cited Brand in Proteins: With over 35 years of providing the best recombinant proteins to the scientific community, R&D Systems continues to lead the industry in quality, activity, and purity.

Find the non-Fc, His-tagged PD-L1 protein here PD-L1 His

Visit Bio-Techne to explore other immune checkpoint proteins Immune Checkpoint Proteins

Product Specifications

Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 0.075-0.75 μg/mL.
Source
Mouse myeloma cell line, NS0-derived human PD-L1/B7-H1 protein
Human PD-L1
(Phe19-Thr239)
Accession # Q9NZQ7		 DIEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus
Accession #
Q9NZQ7
N-terminal Sequence
Analysis
Phe19
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
52 kDa (monomer)
SDS-PAGE
70-75 kDa, reducing conditions

Product Datasheets

You must select a language.

x

156-B7

Product Datasheet
COA
SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

156-B7

Formulation Lyophilized from a 0.2 μm filtered solution in PBS and NaCl.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

SEC-MALS View Larger

Recombinant human B7-H1/Fc (Catalog # 156-B7) has a molecular weight (MW) of 135.0 kDa as analyzed by SEC-MALS, suggesting that this protein is a homodimer.  MW may differ from predicted MW due to post-translational modifications (PTMs) present (i.e. Glycosylation).

Bioactivity Graph showing bioactivity of Human PD-L1 protein (B7-H1 protein) View Larger

Recombinant Human PD-L1 / B7-H1 Fc Chimera (Catalog # 156-B7) inhibits anti-CD3 antibody-induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 0.075-0.75 µg/mL in the presence of Goat Anti-Human IgG Fc Polyclonal Antibody (Catalog # G-102-C).

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: PD-L1/B7-H1

PD-L1, also known as B7-H1, PDL1, is one of the ligands for PD-1 and plays a critical role in the regulation of T cell immunity (1-6). The PD-1:PD-L1 interaction initiates a negative signaling cascade in T cells leading to inhibition of T cell activation (2, 5, 7, 8). PD-L1 provides a molecular stop signal to the adaptive immune system helping to distinguish between self and foreign antigens. PD-L1 also plays a role in the development of immune tolerance by promoting T cell anergy (1, 5) and enhancing regulatory T cell development (8). In addition, PD-L1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (7, 9) and inhibits the development of Th17 cells (8). Many cancers exhibit upregulated PD-L1 protein expression, and several cancers with high levels of PD-L1 have been associated with increased tumor aggressiveness and poor prognosis. Using new therapeutics that block the PD-L1:PD-1 interaction has proven successful in the clinic for many cancer types and has sparked great interest in the field of cancer immunotherapy.

The PD-L1 protein is an approximately 65 kDa transmembrane glycoprotein belonging to the B7 family of immune regulatory molecules (10). Mature human PD-L1 protein consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (11). Within the ECD, human PD-L1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (12). PD-L1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (10, 13, 14, 16) keratinocytes (9, 11), endothelial and intestinal epithelial cells (2, 9), as well as a variety of carcinomas and melanoma (12, 16).

References
  1. Tsushima, F. et al. (2007) Blood 110:180.
  2. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
  3. Azuma, T. et al. (2008) Blood 111:3635.
  4. Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
  5. Park, J.-J. et al. (2010) Blood 116:1291.
  6. Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
  7. Chen, L. et al. (2007) J. Immunol. 178:6634.
  8. Herold, M. et al. (2015) J. Immunol. 195:3584.
  9. Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
  10. Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
  11. Dong, H. et al. (1999) Nat. Med. 5:1365.
  12. Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
  13. Tamura, H. et al. (2001) Blood 97:1809.
  14. Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
  15. Cao, Y. et al. (2010) Cancer Res. 71:1235.
  16. Dong, H. et al. (2002) Nat. Med. 8:793.
Long Name
Programmed Death Ligand 1
Entrez Gene IDs
29126 (Human); 60533 (Mouse); 499342 (Rat); 574058 (Porcine); 484186 (Canine); 102145573 (Cynomolgus Monkey)
Alternate Names
Avelumab; B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDCD1LG1MGC142296; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1

Citations for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

24 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody
    Authors: Rattanapisit, K;Bulaon, CJI;Strasser, R;Sun, H;Phoolcharoen, W;
    Scientific reports
    Species: Human
    Sample Types: Recombinant Protein
    Applications: ELISA Standard
  2. Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells
    Authors: O Munoz, R Banga, R Schelling, FA Procopio, A Mastrangel, P Nortier, K Ohmiti, J Daraspe, M Cavassini, C Fenwick, L Perez, M Perreau
    PloS Pathogens, 2022-07-05;18(7):e1010673.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. High mobility group protein B1 decreases surface localization of PD-1 to augment T-cell activation
    Authors: Q Gao, S Wang, F Li, J Lian, S Cheng, D Yue, Z Zhang, S Liu, F Ren, D Zhang, S Wang, L Wang, Y Zhang
    Cancer Immunology Research, 2022-07-01;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors
    Authors: AP Curnock, G Bossi, J Kumaran, LJ Bawden, R Figueiredo, R Tawar, K Wiseman, E Henderson, SJ Hoong, V Gonzalez, H Ghadbane, DEO Knight, R O'Dwyer, DX Overton, CM Lucato, NMG Smith, CR Reis, K Page, LM Whaley, ML McCully, S Hearty, TM Mahon, P Weber
    JCI Insight, 2021-10-22;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Oral immune dysfunction is associated with the expansion of FOXP3+PD-1+Amphiregulin+ T cells during HIV infection
    Authors: N Bhaskaran, E Schneider, F Faddoul, A Paes da Si, R Asaad, A Talla, N Greenspan, AD Levine, D McDonald, J Karn, MM Lederman, P Pandiyan
    Nature Communications, 2021-08-26;12(1):5143.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Protein detection in blood with single-molecule imaging
    Authors: CP Mao, SC Wang, YP Su, SH Tseng, L He, AA Wu, RBS Roden, J Xiao, CF Hung
    Science Advances, 2021-08-11;7(33):.
    Species: Human
    Sample Types: Reference Standard
  7. Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child
    Authors: M Ogishi, R Yang, C Aytekin, D Langlais, M Bourgey, T Khan, FA Ali, M Rahman, OM Delmonte, M Chrabieh, P Zhang, C Gruber, SJ Pelham, AN Spaan, J Rosain, WT Lei, S Drutman, MD Hellmann, MK Callahan, M Adamow, P Wong, JD Wolchok, G Rao, CS Ma, Y Nakajima, T Yaguchi, K Chamoto, SC Williams, JF Emile, F Rozenberg, MS Glickman, F Rapaport, G Kerner, G Allington, I Tezcan, D Cagdas, FO Hosnut, F Dogu, A Ikinciogul, VK Rao, L Kainulaine, V Béziat, J Bustamante, S Vilarinho, RP Lifton, B Boisson, L Abel, D Bogunovic, N Marr, LD Notarangel, SG Tangye, T Honjo, P Gros, S Boisson-Du, JL Casanova
    Nature Medicine, 2021-06-28;0(0):.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  8. Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
    Authors: C Vetrei, M Passariell, G Froechlich, R Rapuano Le, N Zambrano, C De Lorenzo
    Cancers, 2021-06-08;13(12):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  9. Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)
    Authors: J Huetter, U Gritzan, I Gutcher, WD Doecke, MV Luetke-Eve, S Golfier, HG Roider, AL Frisk, J Hunter, A Pow, A Drake, Z Levine, O Levy, M Azulay, I Barbiro, G Cojocaru, I Vaknin, B Kreft, L Roese
    Cancer Immunol Res, 2020-04-20;8(7):895-911.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Targeting glycosylated PD-1 induces potent anti-tumor immunity
    Authors: L Sun, CW Li, EM Chung, R Yang, YS Kim, AH Park, YJ Lai, Y Yang, YH Wang, J Liu, Y Qiu, KH Khoo, J Yao, JL Hsu, JH Cha, LC Chan, JM Hsu, HH Lee, SS Yoo, MC Hung
    Cancer Res., 2020-03-10;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries
    Authors: B Cembrola, V Ruzza, F Troise, ML Esposito, E Sasso, V Cafaro, M Passariell, F Visconte, M Raia, L Del Vecchi, AM D'Alise, R Cortese, E Scarselli, N Zambrano, C De Lorenzo, A Nicosia
    Biomed Res Int, 2019-12-28;2019(0):6051870.
    Species: Yeast, Yeast - Saccharomyces cerevisiae
    Sample Types: Whole Cell
    Applications: Binding Assay
  12. LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer
    Authors: KJ Carpenter, AC Valfort, N Steinauer, A Chatterjee, S Abuirqeba, S Majidi, M Sengupta, RJ Di Paolo, LP Shornick, J Zhang, CA Flaveny
    Sci Rep, 2019-12-20;9(1):19530.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
    Authors: W Fu, C Lei, S Liu, Y Cui, C Wang, K Qian, T Li, Y Shen, X Fan, F Lin, M Ding, M Pan, X Ye, Y Yang, S Hu
    Nat Commun, 2019-09-25;10(1):4355.
    Species: Human
    Sample Types: Whole Cells
    Applications: CAR-T (Bioassay)
  14. Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery
    Authors: JK Fierle, J Abram-Sali, M Brioschi, M deTiani, G Coukos, SM Dunn
    Sci Rep, 2019-09-06;9(1):12815.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  15. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients
    Authors: A Osa, T Uenami, S Koyama, K Fujimoto, D Okuzaki, T Takimoto, H Hirata, Y Yano, S Yokota, Y Kinehara, Y Naito, T Otsuka, M Kanazu, M Kuroyama, M Hamaguchi, T Koba, Y Futami, M Ishijima, Y Suga, Y Akazawa, H Machiyama, K Iwahori, H Takamatsu, I Nagatomo, Y Takeda, H Kida, EA Akbay, PS Hammerman, KK Wong, G Dranoff, M Mori, T Kijima, A Kumanogoh
    JCI Insight, 2018-10-04;3(19):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  16. Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy
    Authors: UM Vogl, L Öhler, M Rasic, JM Frischer, M Modak, J Stöckl
    Anticancer Res., 2017-04-01;37(4):1947-1955.
    Applications: ELISA (Standard)
  17. Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice
    Authors: E Burova, A Hermann, J Waite, T Potocky, V Lai, S Hong, M Liu, O Allbritton, A Woodruff, Q Wu, A D'Orvillie, E Garnova, A Rafique, W Poueymirou, J Martin, T Huang, D Skokos, J Kantrowitz, J Popke, M Mohrs, D MacDonald, E Ioffe, W Olson, I Lowy, A Murphy, G Thurston
    Mol. Cancer Ther, 2017-03-06;0(0):.
    Applications: Bioassay
  18. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells
    Sci Rep, 2016-11-08;6(0):36722.
    Species: Human
    Sample Types: Protein
    Applications: ELISA (Standard)
  19. Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
    Authors: Robert L Ferris
    Oncoimmunology, 2016-09-22;5(10):e1200778.
    Applications: Bioassay
  20. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.
    Authors: Li J, Jie H, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane L, Ferris R
    Cancer Res, 2014-12-05;75(3):508-18.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  21. Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients.
    Authors: Melendreras S, Martinez-Camblor P, Menendez A, Bravo-Mendoza C, Gonzalez-Vidal A, Coto E, Diaz-Corte C, Ruiz-Ortega M, Lopez-Larrea C, Suarez-Alvarez B
    PLoS ONE, 2014-12-05;9(12):e113396.
    Species: Human
    Sample Types: Serum
    Applications: ELISA (Standard)
  22. IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells.
    Authors: Chinnadurai R, Copland I, Patel S, Galipeau J
    J Immunol, 2014-01-08;192(4):1491-501.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  23. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
    Authors: Steidl C, Shah SP, Woolcock BW
    Nature, 2011-03-02;471(7338):377-81.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  24. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis.
    Authors: Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ
    J. Immunol., 2006-12-15;177(12):8844-50.
    Species: Human
    Sample Types: N/A, Whole Cells
    Applications: Bioassay, ELISA (Standard)

FAQs

  1. What is the pI (Isoelectric Point) of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7)?

    • The calculated pI for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7) is 7.1.

  2. Do you have a human IgG1 Fc region that would be a suitable negative control for the linker sequence and Fc region in Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7)?

    • Yes, we offer Recombinant Human IgG1 Fc Protein, CF (Catalog # 110-HG), which contains the human IgG Fc region and linker sequence.

  3. Has Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7), been evaluated on primary cells?

    • Bioactivity of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7) is evaluated by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocyte primary cells. The ED50 for this effect is 0.075-0.75 μg/mL. We recommend reviewing our list of publications under the Citations tab on the product-specific web page to find reported use of our products in similar experimental layouts.

  4. What are the differences between Recombinant Human PD-L1/B7-H1 His-tag Protein, CF (Catalog # 9049-B7) and Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7)?

    • Recombinant Human PD-L1/B7-H1 Protein, CF (Catalog # 9049-B7) consists of (Phe19-Thr239) from Accession # Q9NZQ7. It has a His tag but no Fc chimera. Activity for 9049-B7 is measured in a binding assay with Recombinant Human PD‑1 Fc Chimera (Catalog # 1086-PD). Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog 156-B7) consists of the same region (Phe19-Thr239), but instead of a His tag, it has a linker region and an Fc chimera. Activity for 156-B7 is assessed in a cell-based assay measuring IL-2 production by human T lymphocytes.

View all Proteins and Enzyme FAQs
Loading...

Reviews for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Average Rating: 4.9 (Based on 21 Reviews)

5 Star
90.48%
4 Star
4.76%
3 Star
4.76%
2 Star
0%
1 Star
0%

Have you used Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 06/19/2020
Application: Binding assay/Protein-protein interaction
Reason for Rating: Tested binding of PDL1-Fc w/ PD-1 using Octet. KD ~1.5uM
Binding assay/Protein-protein interaction Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF 156-B7
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Sarah Garrett on 11/15/2019
Application: Binding assay/Protein-protein interaction

HEK cells expressing mCherry alone (LEFT) or hPD-1 mCherry (RIGHT) were incubated with 0.25 ug of hPD-L1 hIgG1. Binding was monitored by flow cytometry using an anti-human 488 secondary antibody.

Binding assay/Protein-protein interaction Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF 156-B7
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Jenna Nguyen on 12/06/2018
Application: Stem/Immune cell maintenance or differentiation
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Jenna Nguyen on 10/24/2018
Application: Cell Adhesion
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Jenna Nguyen on 10/12/2018
Application: Enzymatic activity in vitro
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Jenna Nguyen on 09/28/2018
Application: CellProlif
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 08/26/2018
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 04/12/2018
Application: SDS-PAGE Control
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 03/30/2018
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 03/15/2018
Application: SDS-PAGE Control
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 03/11/2018
Application: SDS-PAGE Control
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 02/07/2018
Application: Binding assay/Protein-protein interaction
Reason for Rating: Binding observed.
Binding assay/Protein-protein interaction Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF 156-B7
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Amit Kumar on 12/18/2017
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 12/06/2017
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Konrad Gabrusiewicz on 12/01/2017
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 11/27/2017
Application: Binding assay/Protein-protein interaction
Binding assay/Protein-protein interaction Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF 156-B7
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 11/18/2017
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Jenna Nguyen on 07/20/2017
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 07/20/2017
Application: Cell Adhesion
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 07/14/2017
Application: SPR assay for Kinetics between PDL-1 and AntiPDL-1 Antibody

SPR experiment

Other Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF 156-B7
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 05/23/2017

Using Octet, we tested the ability of B7-H1/PD-L1 to bind recombinant PD-1 (R&D 8986-PD-100) and found them to specifically bind to each other.

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF 156-B7